Search Page

1

Cite

Share

Rational basis for Trk inhibition therapy for prostate cancer.

Weeraratna AT, Arnold JT, George DJ, DeMarzo A, Isaacs JT. Weeraratna AT, et al. Prostate. 2000 Oct 1;45(2):140-8. doi: 10.1002/1097-0045(20001001)45:2<140::aid-pros8>3.0.co;2-#. Prostate. 2000. PMID: 11027413

Cite

Share

2

Cite

Share

Characterization of an endogenous RNA transcript with homology to the antisense strand of the human c-myc gene.

Celano P, Berchtold CM, Kizer DL, Weeraratna A, Nelkin BD, Baylin SB, Casero RA Jr. Celano P, et al. J Biol Chem. 1992 Jul 25;267(21):15092-6. J Biol Chem. 1992. PMID: 1378845

Cite

Share

3

Cite

Share

Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells.

Tombal B, Weeraratna AT, Denmeade SR, Isaacs JT. Tombal B, et al. Among authors: weeraratna at. Prostate. 2000 Jun 1;43(4):303-17. doi: 10.1002/1097-0045(20000601)43:4<303::aid-pros10>3.0.co;2-v. Prostate. 2000. PMID: 10861750

Cite

Share

4

Cite

Share

Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.

Weeraratna AT, Dalrymple SL, Lamb JC, Denmeade SR, Miknyoczki S, Dionne CA, Isaacs JT. Weeraratna AT, et al. Clin Cancer Res. 2001 Aug;7(8):2237-45. Clin Cancer Res. 2001. PMID: 11489797

Cite

Share

5

Cite

Share

Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts.

Pinski J, Weeraratna A, Uzgare AR, Arnold JT, Denmeade SR, Isaacs JT. Pinski J, et al. Cancer Res. 2002 Feb 15;62(4):986-9. Cancer Res. 2002. PMID: 11861369

Cite

Share

6

Cite

Share

Uteroglobin: a potential novel tumor suppressor and molecular therapeutic for prostate cancer.

Patierno SR, Manyak MJ, Fernandez PM, Baker A, Weeraratna AT, Chou DS, Szlyk G, Geib KS, Walsh C, Patteras J. Patierno SR, et al. Among authors: weeraratna at. Clin Prostate Cancer. 2002 Sep;1(2):118-24. doi: 10.3816/cgc.2002.n.014. Clin Prostate Cancer. 2002. PMID: 15046703 Review.

Cite

Share

7

Cite

Share

Interleukin-1 alpha mediates the growth proliferative effects of transforming growth factor-beta in p21 null MCF-10A human mammary epithelial cells.

Karakas B, Weeraratna A, Abukhdeir A, Blair BG, Konishi H, Arena S, Becker K, Wood W 3rd, Argani P, De Marzo AM, Bachman KE, Park BH. Karakas B, et al. Oncogene. 2006 Sep 7;25(40):5561-9. doi: 10.1038/sj.onc.1209540. Epub 2006 Apr 17. Oncogene. 2006. PMID: 16619041

Cite

Share

8

Cite

Share

The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition.

Dissanayake SK, Wade M, Johnson CE, O'Connell MP, Leotlela PD, French AD, Shah KV, Hewitt KJ, Rosenthal DT, Indig FE, Jiang Y, Nickoloff BJ, Taub DD, Trent JM, Moon RT, Bittner M, Weeraratna AT. Dissanayake SK, et al. Among authors: weeraratna at. J Biol Chem. 2007 Jun 8;282(23):17259-71. doi: 10.1074/jbc.M700075200. Epub 2007 Apr 10. J Biol Chem. 2007. PMID: 17426020 Free PMC article.

Cite

Share

9

Cite

Share

Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells.

O'Connell MP, Fiori JL, Kershner EK, Frank BP, Indig FE, Taub DD, Hoek KS, Weeraratna AT. O'Connell MP, et al. Among authors: weeraratna at. J Biol Chem. 2009 Oct 16;284(42):28704-12. doi: 10.1074/jbc.M109.028498. Epub 2009 Aug 20. J Biol Chem. 2009. PMID: 19696445 Free PMC article.

Cite

Share

10

Cite

Share

The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma.

O'Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC, French AD, Dissanayake SK, Indig FE, Bernier M, Taub DD, Hewitt SM, Weeraratna AT. O'Connell MP, et al. Among authors: weeraratna at. Oncogene. 2010 Jan 7;29(1):34-44. doi: 10.1038/onc.2009.305. Epub 2009 Oct 5. Oncogene. 2010. PMID: 19802008 Free PMC article.

Cite

Share